| scholarly article | Q13442814 |
| P2093 | author name string | Michael Schäfers | |
| Matthias Weckesser | |||
| Kambiz Rahbar | |||
| Martin Boegemann | |||
| Robert Seifert | |||
| Katharina Kessel | |||
| Katrin Schlack | |||
| P2860 | cites work | Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Q30277291 |
| Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases | Q30572057 | ||
| German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients | Q33436183 | ||
| Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. | Q33441176 | ||
| Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients | Q33841484 | ||
| Mechanisms of resistance to cabazitaxel. | Q35661531 | ||
| Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer | Q35948297 | ||
| Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer | Q37709519 | ||
| 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer | Q38720855 | ||
| Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer | Q38773250 | ||
| Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. | Q38861197 | ||
| Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer | Q38879864 | ||
| Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. | Q40208178 | ||
| Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate Cancer | Q41485921 | ||
| Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'? | Q42756677 | ||
| Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial | Q46131083 | ||
| Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. | Q48107095 | ||
| PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. | Q48194472 | ||
| The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. | Q50777449 | ||
| [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. | Q53779588 | ||
| Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. | Q53790732 | ||
| Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer | Q58798456 | ||
| [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study | Q88645082 | ||
| Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer | Q90356310 | ||
| An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA) | Q90884310 | ||
| Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer | Q91071991 | ||
| Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer | Q93352125 | ||
| P433 | issue | 17 | |
| P921 | main subject | lutetium-177 | Q18882670 |
| P304 | page(s) | 4841-4848 | |
| P577 | publication date | 2019-07-09 | |
| P1433 | published in | Theranostics | Q21051383 |
| P1476 | title | Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617 | |
| P478 | volume | 9 |
| Q89848845 | 68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study |
| Q90481802 | Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria |
| Q96764719 | Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer |
| Q92423962 | ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors |
| Q92063519 | Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy |
| Q89731386 | Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis |
Search more.